FindTrial
Sign In

The effect of trichloromethiazide in autosomal dominant polycystic kidney disease patients using tolvaptan: randomized crossover controlled trial

The effect of trichloromethiazide in autosomal dominant polycystic kidney disease patients using tolvaptan: randomized crossover controlled trial - The effect of trichloromethiazide in autosomal dominant polycystic kidney disease patients using tolvaptan

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000037550
Enrollment
10
Registered
2019-07-31
Start date
2019-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autosomal dominant polycystic kidney disease

Interventions

Antihypertensive treatment including trichloromethiazide Standard antihypertensive treatment (without the use of trichloromethiazide)

Sponsors

Division of Nephrology, Japanese Red Cross Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Hypertensive ADPKD patients using tolvaptan

Exclusion criteria

Exclusion criteria: Exclusion criteria are as follows: patients with uncontrolled persistent hypertension (systolic blood pressure >= 180 mmHg or diastolic pressure >= 110 mmHg); Hyponatremia (serum Na < 135 mEq/L) and/or hypokalemia (serum K < 3.5 mEq/L); prior symptomatic coronary artery or cerebrovascular diseases within the previous 3 months; uncontrolled heart failure (NYHA >= III); symptomatic or lethal arrhythmia; severe valvular diseases.

Design outcomes

Primary

MeasureTime frame
Urine volume with urinary osmolality—

Secondary

MeasureTime frame
Renal function, HRQOL, serum/urinary electrolyte, biomarker, blood pressure—

Countries

Japan

Contacts

Public ContactKiyotaka Uchiyama

Keio University School of Medicine Division of Endocrinology, Metabolism and Nephrology Department of Internal Medicine

kiyo.0817.piyo@keio.jp03-5363-3796

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026